Multinational pharmaceutical companies to prepare for the age of anticancer antibody
Multinational pharmaceutical companies, which entered the anticancer field with anticancer immunotherapies, have made severe competition to preoccupy the market.
Recently, MSD Korea acquired approval to conduct clinical trials of ‘Keytruda(pembrolizumab)’ an anti-PD-1 immunotherapy, called ‘KEYN...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
